MLR Review Tools and Workflow: What Speeds Approval
What MLR review tools do, how to set up a faster medical, legal, and regulatory review workflow, modular content, AI assistance, and metrics to track.
The short answer
MLR review tools manage the submission, annotation, routing, approval, and expiry of promotional materials for medical, legal, and regulatory review. They speed approval when combined with good workflow: complete submissions with references, modular pre-approved content, clear reviewer roles, early review for new formats, and tracking of review rounds and rejection reasons. AI features can help check references and flag issues, but reviewers still decide.
Review is often blamed for slow campaigns. Sometimes it deserves the blame. More often, slow review comes from incomplete submissions, late changes, and new formats that reviewers see for the first time a week before launch. Tools help, but workflow matters more.
What MLR tools do
| Function | Purpose |
|---|---|
| Submission | Upload materials with metadata and references |
| Routing | Send to the right reviewers in order or in parallel |
| Annotation | Comments tied to specific parts of the asset |
| Reference linking | Connect each claim to its source |
| Approval and versioning | Record who approved which version |
| Expiry and withdrawal | Retire materials on schedule |
| Reporting | Cycle times, rounds, reasons for changes |
Several vendors offer promotional review platforms, often within broader content management systems. Compare on integration with your content tools, reference management, and reporting.
Workflow habits that speed approval
- Complete submissions. Every claim referenced, every format shown as it will run.
- Modular content. Pre-approved blocks reduce new review.
- Early review for new formats. Show reviewers a CTV interactive unit or a social format before building the campaign.
- Clear roles. Each reviewer knows what they own.
- Fewer late changes. Lock strategy and claims before production.
- Feedback loops. Track rejection reasons and fix their causes.
Modular content
Modular approaches pre-approve claims, risk statements, and visuals with rules for combining them. Benefits:
- Faster approval of new combinations.
- Consistency across channels.
- Safer dynamic creative.
Risks: combinations that are each approved but misleading together. Rules must cover combinations, not just parts.
AI in MLR
AI can help with:
- Checking that claims match references.
- Flagging missing risk statements.
- Comparing new assets with approved versions.
- Summarizing changes between versions.
It should not make approval decisions. Keep records of what AI flagged and how reviewers responded. See testing AI recommendations for a related approach.
Metrics to track
- Median days from submission to approval.
- Average review rounds per asset.
- Top rejection reasons.
- Share of submissions incomplete on first submission.
- Share of assets using modular content.
Programmatic and media specifics
Media formats bring their own review issues: dozens of sizes, dynamic elements, and platform-specific specs. See MLR review for programmatic media.
Common mistakes
- Buying a tool without fixing submission quality.
- Modular content without combination rules.
- Treating AI flags as approval.
- No reporting on why materials are rejected.
Practical takeaway
Measure your average review rounds per asset and the top three rejection reasons for one quarter. Fix the top reason at its source, usually an incomplete submission or a missing reference, before investing in new tooling.
Frequently asked questions
What does MLR stand for?
Medical, legal, and regulatory. It refers to the review of promotional materials by those three functions before use.
What do MLR tools do?
They store submissions, route them to reviewers, capture comments and annotations, link claims to references, record approvals, and manage expiry and withdrawal.
What is modular content in MLR?
Pre-approved content blocks, such as claims, risk statements, and images, that can be combined under approved rules, reducing the need to review every asset from scratch.
Sources
External guidance and platform documentation change. Links were current at publication; check them again before relying on them for a decision.
Editorial note. Analysis and frameworks are the author's own and do not represent Acxiom or any current or former employer, client, or named platform. Examples labeled hypothetical or illustrative are not results from real campaigns. Nothing here is legal, regulatory, or medical advice.
New pharma programmatic breakdowns, occasionally
One email when I publish something worth reading. Benchmarks, measurement teardowns, and case studies with the caveats attached. No cadence promises, no reselling your address.
Unsubscribe any time. See the privacy policy.
Working through this decision on a real plan?
I work on health and pharma data, identity, and activation, after five years running HCP and DTC programmatic agency-side. Happy to talk through how this applies to your situation.